香港股市 已收市

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM 即時價格。貨幣為 USD。
加入追蹤清單
20.29-0.13 (-0.64%)
收市:04:00PM EDT
20.14 -0.15 (-0.74%)
收市後: 06:07PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價20.42
開市20.26
買盤20.19 x 300
賣出價20.34 x 200
今日波幅20.02 - 20.68
52 週波幅12.32 - 32.10
成交量468,359
平均成交量686,209
市值877.457M
Beta 值 (5 年,每月)-0.42
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-2.32
業績公佈日2024年4月29日 - 2024年5月03日
遠期股息及收益率無 (無)
除息日2012年12月13日
1 年預測目標價
  • InvestorPlace

    Exit Now! 3 Biotech Stocks to Sell in February 2024

    The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges. Moreover, despite forecasts pointing to a potential rebound in 2024, the biotech industry is struggling to adapt post-pandemic. For many biotech firms, securing private funding and launching successful IPOs remains a daunting tas

  • Motley Fool

    Is There Any Hope for Cassava Sciences Stock?

    Battered by controversy, this company will need to show real results to prosper.

  • InvestorPlace

    3 Biotech Stocks to Sell in January Before They Crash and Burn

    The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies’ performance relies heavily on drug approvals. A major drug approval has the potential to multiply stock price several times, while a failure to reach approval may cause an immediate, sharp decline. For the following reasons, it is important to choose biotech investments carefully. Below are th